YYC506-A

YYC506-A is one component of the fixed-dose combination drug known as YYC 506, which consists of two agents, YYC506T and YYC506A. This combination is being developed by Yooyoung Pharmaceutical for the treatment of dyslipidemias, specifically targeting patients whose LDL cholesterol (LDL-C) is properly controlled but who continue to have abnormal triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C) levels despite atorvastatin therapy[1][3][6]. The mechanism of action and specific molecular target(s) for YYC506-A are not disclosed in public sources. Clinical trials have evaluated the safety, pharmacokinetics, and drug-drug interactions between the components in healthy volunteers[3][4][5]. The overall fixed-dose combination has reached Phase 3 clinical development for hyperlipidemias/dyslipidemia[2][6].